Biotech startups that raised Series B in Jiangsu, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Yuce Biotechnology | Suzhou | Series B | $7.4M | 2026-08-31 |
| HemaCell | Suzhou | Series B | $14.8M | 2026-06-02 |
| D3 Bio | Wuxi Shi | Series B | $108.0M | 2025-12-09 |
| CureGenetics | Suzhou | Series B | $9.0M | 2024-03-28 |
| Onechip Bioelectronics | Zhangjiagang | Series B | $13.7M | 2023-09-28 |
5 rows of the CSV in 5 of its 18 columns.
- The 46 biotech startups in Jiangsu, China whose last round is Series B have raised $1.6B in total.
- 10 of them closed their most recent round in the last 12 months, $228.4M combined.
- The largest of those rounds is D3 Bio's $108.0M Series B, dated December 2025.
- The most recent is Yuce Biotechnology's $7.4M Series B on 31 August 2026.
- Matrix Partners China is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 43 companies (93%).
- 22% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 101 to 250 employees (27% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
5 of 46| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| CureGenetics | CureGenetics develops medicines and molecular diagnostics for cancers and genetic diseases. | Biotech | Suzhou | Series B | $9.0M | 2024-03-28 | Qiming Venture Partners, Oriza Holdings, Qingsong Fund +1 | 51 to 100 | 2016 | |
| Onechip Bioelectronics | Onechip Bioelectronics develops biosensor chips and nanomaterials. | Biotech | Zhangjiagang | Series B | $13.7M | 2023-09-28 | Matrix Partners China, Qiming Venture Partners, Xiamen C&D Emerging Industry Equity Investment +1 | 11 to 50 | 2014 |
Table 1. Biotech startups that raised Series B in Jiangsu, China: the 5 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 46.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 2 | HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| 3 | Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
Table 2. Biotech startups that raised Series B in Jiangsu, China: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Matrix Partners China | Venture capital firm | Beijing, China | 2 | 4% | 1 | D3 Bio |
| 2 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 4% | ||
| 3 | LH Ventures | Private equity firm | Shanghai, China | 1 | 2% | 1 | Yuce Biotechnology |
| 4 | BioTrack Capital | Venture capital firm | Shanghai, China | 1 | 2% | 1 | Yuce Biotechnology |
| 5 | Boyuan Capital | Venture capital firm | Shanghai, China | 1 | 2% | 1 | Yuce Biotechnology |
| 6 | Zhengxuan Investment | Venture capital firm | Shenzhen, China | 1 | 2% | 1 | Yuce Biotechnology |
| 7 | Puhua Capital | Venture capital firm | Hangzhou, China | 1 | 2% | 1 | Yuce Biotechnology |
| 8 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 1 | 2% | 1 | HemaCell |
| 9 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 1 | 2% | 1 | HemaCell |
| 10 | CMB International Capital Corporation | Investment bank | Central, Hong Kong | 1 | 2% | 1 | HemaCell |
| 11 | Boyu Capital | Private equity firm | Beijing, China | 1 | 2% | 1 | D3 Bio |
| 12 | Medicxi | Venture capital firm | London, United Kingdom | 1 | 2% | 1 | D3 Bio |
| 13 | Huatai Zijin Investment | Venture capital firm | Nanjing, China | 1 | 2% | 1 | Puguang Bio |
| 14 | Advantech Capital | Private equity firm | Central, Hong Kong | 1 | 2% | ||
| 15 | Qingsong Fund | Venture capital firm | Shenzhen, China | 1 | 2% |
Table 3. Biotech startups that raised Series B in Jiangsu, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 43 | 93% | $1.5B |
| Hardware | 1 | 2% |
Table 4. Biotech startups that raised Series B in Jiangsu, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 46 | 100% | $28.7M |
Table 5. Biotech startups that raised Series B in Jiangsu, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Suzhou | 28 | 61% |
| Nanjing | 11 | 24% |
| Taizhou | 2 | 4% |
| Nantong | 1 | 2% |
| Wuxi Shi | 1 | 2% |
| Zhangjiagang | 1 | 2% |
| Yangzhou | 1 | 2% |
| Jiangyin | 1 | 2% |
Table 6. Biotech startups that raised Series B in Jiangsu, China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| August 2026 | 1 | 10% | $7.4M |
| June 2026 | 1 | 10% | $14.8M |
| May 2026 | 2 | 20% | $54.7M |
| January 2026 | 3 | 30% | $29.2M |
| December 2025 | 2 | 20% | $122.3M |
| November 2025 | 1 | 10% |
Table 7. Biotech startups that raised Series B in Jiangsu, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 7 | 15% | $106.1M |
| 2025 | 7 | 15% | $122.3M |
| 2024 | 4 | 9% | $27.0M |
| 2023 | 8 | 17% | $238.8M |
| 2022 | 7 | 15% | $271.8M |
| 2021 | 3 | 7% | $154.8M |
Table 8. Biotech startups that raised Series B in Jiangsu, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 10 | 22% |
| 2015 to 2019 | 21 | 46% |
| 2010 to 2014 | 10 | 22% |
| Before 2010 | 5 | 11% |
Table 9. Biotech startups that raised Series B in Jiangsu, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 5 | 12% |
| 11 to 50 | 9 | 22% |
| 51 to 100 | 8 | 20% |
| 101 to 250 | 11 | 27% |
| 251 to 500 | 5 | 12% |
| 501 to 1,000 | 3 | 7% |
Table 10. Biotech startups that raised Series B in Jiangsu, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in Jiangsu, China. On 16 November 2026 that is 46 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 5 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 46 rows: 12 have no round amount, 0 no city and 9 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Jiangsu, China whose last round is Series B are on the list?
- 46, in the file dated 16 November 2026. 10 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 46 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.